Lotiglipron
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
Pfizer · Phase 2 · Terminated · Enrollment 902
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| PF-07081532 20 mg T2DM | Obesity + T2D | 20 mg | 36 | n/r | n/r |
| PF-07081532 40 mg T2DM | Obesity + T2D | 40 mg | 36 | n/r | n/r |
| PF-07081532 80 mg T2DM | Obesity + T2D | 80 mg | 36 | n/r | n/r |
| PF-07081532 160 mg T2DM | Obesity + T2D | 160 mg | 36 | n/r | n/r |
| PF-07081532 260 mg T2DM | Obesity + T2D | 260 mg | 36 | n/r | n/r |
| Placebo T2DM | Obesity + T2D | n/r | 36 | n/r | n/r |
| PF-07081532 80 mg Obesity | Obesity + T2D | 80 mg | 36 | n/r | n/r |
| PF-07081532 140 mg Obesity | Obesity + T2D | 140 mg | 36 | n/r | n/r |
| PF-07081532 200 mg Obesity (Option 1) | Obesity + T2D | 200 mg | 36 | n/r | n/r |
| PF-07081532 200 mg Obesity (Option 2) | Obesity + T2D | 200 mg | 36 | n/r | n/r |
| PF-07081532 260 mg Obesity | Obesity + T2D | 260 mg | 36 | n/r | n/r |
| Rybelsus 14 mg T2DM | Obesity + T2D | 14 mg | 36 | n/r | n/r |
| Placebo Obesity | Obesity + T2D | n/r | 36 | n/r | n/r |